All News about Edesa Biotech, Inc. - Common Shares


Via ACCESSWIRE

Via ACCESSWIRE

Edesa Biotech's Dermatitis Study Data Fails To Cheer Investors
January 17, 2023
Via Benzinga

Edesa Biotech Announces One-for-Seven Reverse Share Split
October 10, 2023
Via ACCESSWIRE


Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
September 28, 2023
Via ACCESSWIRE

Edesa Biotech Reports Fiscal Third Quarter 2023 Results
August 09, 2023
Via ACCESSWIRE





Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
June 27, 2023
Via ACCESSWIRE

Via ACCESSWIRE

Edesa Biotech to Participate in Swiss Biotech Day
April 20, 2023
Via ACCESSWIRE

Via ACCESSWIRE




Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
February 10, 2023
Via ACCESSWIRE

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
February 01, 2023
Via ACCESSWIRE






Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
January 17, 2023
Via ACCESSWIRE



FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate
December 20, 2022
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.